The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity
Abstract
Therapeutic vaccination trials, in which patients with cancer were vaccinated with minimal CTL peptide in oil-in-water formulations, have met with limited success. Many of these studies were based on the promising data of mice studies, showing that vaccination with a short synthetic peptide in IFA results in protective CD8+ T cell immunity. By use of the highly immunogenic OVA CTL peptide in IFA as a model peptide-based vaccine, we investigated why minimal CTL peptide vaccines in IFA performed so inadequately to allow full optimization of peptide vaccination. Injection of the minimal MHC class I-binding OVA257–264 peptide in IFA transiently activated CD8+ effector T cells, which eventually failed to undergo secondary expansion or to kill target cells, as a result of a sustained and systemic presentation of the CTL peptides gradually leaking out of the IFA depot without systemic danger signals. Complementation of this vaccine with the MHC class II-binding Th peptide (OVA323–339) restored both secondary expansion and in vivo effector functions of CD8+ T cells. Simply extending the CTL peptide to a length of 30 aa also preserved these CD8+ T cell functions, independent of T cell help, because the longer CTL peptide was predominantly presented in the locally inflamed draining lymph node. Importantly, these functional differences were reproduced in two additional model Ag systems. Our data clearly show why priming of CTL with minimal peptide epitopes in IFA is suboptimal, and demonstrate that the use of longer versions of these CTL peptide epitopes ensures the induction of sustained effector CD8+ T cell reactivity in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationA conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,092
Induction by Antigen of Intrathymic Apoptosis of CD4 + CD8 + TCR lo Thymocytes in Vivo
Murphy, K. M., Heimberger, A. B., & Loh, D. Y. (1990) · Science · doi:10.1126/science.2125367 · Cited by 1,735
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Introduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092
Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minnaar, R. P., De Jongh, B. M., Drijfhout, J. W., Schegget, J. T., Melief, C. J. M., & Kast, W. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230929 · Cited by 825
Self-citationSpörri, R., & Reis e Sousa, C. (2005) · Nature Immunology · doi:10.1038/ni1162 · Cited by 626
Ossendorp, F., Mengedé, E., Camps, M., Filius, R., & Melief, C. J. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.693 · Cited by 610
Self-citationDiehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I. H., Schumacher, T. N. M., Melief, C. J. M., Offringa, R., & Toes, R. E. M. (1999) · Nature Medicine · doi:10.1038/10495 · Cited by 469
Self-citationZwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 417
Self-citationDynamic programming of CD8+ T lymphocyte responses
van Stipdonk, M. J. B., Hardenberg, G., Bijker, M. S., Lemmens, E. E., Droin, N. M., Green, D. R., & Schoenberger, S. P. (2003) · Nature Immunology · doi:10.1038/ni912 · Cited by 401 · cited 1×
“In order to determine whether vaccination resulted in effector CD8+ T-cells, an in vivo cytotoxicity assay was performed (30).”
BackgroundSelf-citationvan der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3308 · Cited by 394
Self-citationLanzavecchia, A. (1998) · Nature · doi:10.1038/30845 · Cited by 360
Kast, W. M., Roux, L., Curren, J., Blom, H. J., Voordouw, A. C., Meloen, R. H., Kolakofsky, D., & Melief, C. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2283 · Cited by 326
Self-citationPeptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., & Kast, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7855 · Cited by 292
Self-citationT cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides
Kyburz, D., Aichele, P., Speiser, D. E., Hengartner, H., Zinkemagel, R. M., & Pircher, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230834 · Cited by 251
Peptide-induced antiviral protection by cytotoxic T cells.
Schulz, M., Zinkernagel, R. M., & Hengartner, H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.991 · Cited by 238
T cell priming versus T cell tolerance induced by synthetic peptides.
Aichele, P., Brduscha-Riem, K., Zinkernagel, R. M., Hengartner, H., & Pircher, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.261 · Cited by 229
Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3911 · Cited by 208
Self-citationAntiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide.
Aichele, P., Hengartner, H., Zinkernagel, R. M., & Schulz, M. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1815 · Cited by 198
Part I: Vaccines for solid tumours
Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M., & Nitti, D. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01610-9 · Cited by 196
Feltkamp, M. C. W., Vreugdenhil, G. R., Vierboom, M. P. M., Ras, E., van der Burg, S. H., Schegget, J. T., Melief, C. J. M., & Kast, W. M. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250935 · Cited by 166
Self-citationB Cells Directly Tolerize CD8+ T Cells
Bennett, S. R. M., Carbone, F., Toy, T., Miller, J. F. A. P., & Heath, W. R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.1977 · Cited by 158
In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help
Fayolle, C., Dériaud, E., & Leclerc, C. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.12.4069 · Cited by 148
Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization
Huang, L., Biolsi, S., Bales, K. R., & Kuchibhotla, U. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.11.012 · Cited by 144
Ossevoort, M. A., Feltkamp, M. C. W., van Veen, K. J. H., Melief, C. J. M., & Kast, W. M. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199508000-00002 · Cited by 133
Self-citationPeptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.
Aichele, P., Kyburz, D., Ohashi, P. S., Odermatt, B., Zinkernagel, R. M., Hengartner, H., & Pircher, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.444 · Cited by 125
Cytotoxic T Cell Responses to DNA Vaccination: Dependence on Antigen Presentation via Class II MHC
Maecker, H. T., Umetsu, D. T., DeKruyff, R. H., & Levy, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6532 · Cited by 124
Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif
Lipford, G. B., Hoffman, M., Wagner, H., & Heeg, K. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.4.1212 · Cited by 108
Widmann, C., Romero, P. J., Maryanski, J. L., Corradin, G., & Valmori, D. (1992) · Journal of Immunological Methods · doi:10.1016/0022-1759(92)90275-x · Cited by 96
Feltkamp, M. C. W., Vierboom, M., Kast, W. M., & Melief, C. J. M. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90155-4 · Cited by 95
Self-citationShibaki, A., & Katz, S. (2002) · Experimental Dermatology · doi:10.1034/j.1600-0625.2002.110204.x · Cited by 95
Importance of CD4+ T helper cell responses in tumor immunity
OSSENDORP, F. A., Toes, R. E. M., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2000) · Immunology Letters · doi:10.1016/s0165-2478(00)00252-2 · Cited by 92
Self-citationPriming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides
Gao, X. M., Zheng, B. Q., Liew, F. Y., Brett, S. J., & Tite, J. P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.10.3268 · Cited by 87
Minev, B., McFarland, B. J., Spiess, P. J., Rosenberg, S. A., & Restifo, N. P. (1994) · PubMed · Cited by 83
Vaccine and antibody-directed T cell tumour immunotherapy
Dermime, S., Gilham, D. E., Shaw, D. M., Davidson, E. J., Meziane, E. K., Armstrong, A. C., Hawkins, R. E., & Stern, P. L. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.03.002 · Cited by 83
den Boer, A. T., Diehl, L., van Mierlo, G. J. D., van der Voort, E. I. H., Fransen, M. F., Krimpenfort, P., Melief, C. J. M., Offringa, R., & Toes, R. E. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2522 · Cited by 69
Self-citationLipford, G. B., Bauer, S., Wagner, H., et al. (1995) · Vaccine · doi:10.1016/0264-410x(95)93320-9 · Cited by 50
Kast, W. M., Brandt, R. M. P., & Melief, C. J. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230534 · Cited by 44
Self-citationReinholdsson, G., Ramqvist, T., Ährlund‐Richter, L., & Dalianis, T. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500128 · Cited by 28
Hossain, A., Zheng, C., Kukita, A., & Kohashi, O. (2001) · Journal of Autoimmunity · doi:10.1006/jaut.2001.0552 · Cited by 19
Huard, R. (1997) · International Immunology · doi:10.1093/intimm/9.11.1701 · Cited by 15
Rosato, A., Zoso, A., Santa, S. D., Milan, G., Bianco, P. D., Salvo, G. L. D., & Zanovello, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1999 · Cited by 12
Cited by
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Self-citationSaxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Self-citationAdvances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Metadata
- Authors
- Bijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., Offringa, R., & van der Burg, S. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10
- Volume
- 179
- Issue
- 8
- Pages
- 5033-5040
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1488583473
- Cited by
- 279
- References
- 47
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.